<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39371780</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>08</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2168-8184</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Cureus</Title><ISOAbbreviation>Cureus</ISOAbbreviation></Journal><ArticleTitle>Persistent COVID-19 Infection in an Immunocompromised Host: A Case Report.</ArticleTitle><Pagination><StartPage>e68679</StartPage><MedlinePgn>e68679</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e68679</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.7759/cureus.68679</ELocationID><Abstract><AbstractText>This case report highlights the prolonged SARS-CoV-2 reverse transcriptase polymerase chain reaction positivity in a 32-year-old immunocompromised male with a history of kidney transplants and chronic kidney disease. The whole genome sequencing of nasopharyngeal samples for SARS-CoV-2 collected 12 days apart showed the presence of the BA.1.1 Omicron variant. It revealed evidence of intra-host viral evolution, showing the development and loss of specific mutations over time. This report emphasizes the need for continuous monitoring strategies for immunocompromised patients, as they may serve as reservoirs for viral evolution and potentially give rise to immune escape variants.</AbstractText><CopyrightInformation>Copyright © 2024, Das et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Das</LastName><ForeName>Rashmita</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Microbiology, Byramjee Jeejeebhoy Government Medical College and Sassoon General Hospitals, Pune, IND.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karyakarte</LastName><ForeName>Rajesh P</ForeName><Initials>RP</Initials><AffiliationInfo><Affiliation>Microbiology, Byramjee Jeejeebhoy Government Medical College and Sassoon General Hospitals, Pune, IND.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joshi</LastName><ForeName>Suvarna</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Microbiology, Byramjee Jeejeebhoy Government Medical College and Sassoon General Hospitals, Pune, IND.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joy</LastName><ForeName>Marie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Microbiology, Byramjee Jeejeebhoy Government Medical College and Sassoon General Hospitals, Pune, IND.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sadre</LastName><ForeName>Abhay</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Nephrology, Ruby Hall Clinic, Pune, IND.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cureus</MedlineTA><NlmUniqueID>101596737</NlmUniqueID><ISSNLinking>2168-8184</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">covid-19</Keyword><Keyword MajorTopicYN="N">immunocompromised hosts</Keyword><Keyword MajorTopicYN="N">persistent rt-pcr positivity</Keyword><Keyword MajorTopicYN="N">sars-cov-2</Keyword><Keyword MajorTopicYN="N">viral evolution</Keyword></KeywordList><CoiStatement>Human subjects: Consent was obtained or waived by all participants in this study. Institutional Ethics Committee of B. J. Government Medical College and Sassoon General Hospitals issued approval BJGMC/IEC/Pharmac/ND-Dept0721233-233. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>11</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>11</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>5</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39371780</ArticleId><ArticleId IdType="pmc">PMC11452762</ArticleId><ArticleId IdType="doi">10.7759/cureus.68679</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Prolonged severe acute respiratory syndrome coronavirus 2 replication in an immunocompromised patient. Baang JH, Smith C, Mirabelli C, et al. J Infect Dis. 2021;223:23–27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7797758</ArticleId><ArticleId IdType="pubmed">33089317</ArticleId></ArticleIdList></Reference><Reference><Citation>Tracking SARS-CoV-2 Variants.  [
Aug;
2024 
]. 2024. https://www.who.int/activities/tracking-SARS-CoV-2-variants https://www.who.int/activities/tracking-SARS-CoV-2-variants</Citation></Reference><Reference><Citation>Correction to: the origins and molecular evolution of SARS-CoV-2 lineage B.1.1.7 in the UK. Virus Evol. 2022;8:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9802212</ArticleId><ArticleId IdType="pubmed">36601301</ArticleId></ArticleIdList></Reference><Reference><Citation>The origins and potential future of SARS-CoV-2 variants of concern in the evolving COVID-19 pandemic. Otto SP, Day T, Arino J, et al. Curr Biol. 2021;31:918–929.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8220957</ArticleId><ArticleId IdType="pubmed">34314723</ArticleId></ArticleIdList></Reference><Reference><Citation>Using big sequencing data to identify chronic SARS-Coronavirus-2 infections. Harari S, Miller D, Fleishon S, Burstein D, Stern A. Nat Commun. 2024;15:648.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10799923</ArticleId><ArticleId IdType="pubmed">38245511</ArticleId></ArticleIdList></Reference><Reference><Citation>Persistent detection of SARS-CoV-2 RNA in patients and healthcare workers with COVID-19. Gombar S, Chang M, Hogan CA, Zehnder J, Boyd S, Pinsky BA, Shah NH. J Clin Virol. 2020;129:104477.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7260561</ArticleId><ArticleId IdType="pubmed">32505778</ArticleId></ArticleIdList></Reference><Reference><Citation>SARS-CoV-2 viral load and shedding kinetics. Puhach O, Meyer B, Eckerle I. Nat Rev Microbiol. 2023;21:147–161.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9716513</ArticleId><ArticleId IdType="pubmed">36460930</ArticleId></ArticleIdList></Reference><Reference><Citation>Factors associated with prolonged RT-PCR SARS-CoV-2 positive testing in patients with mild and moderate forms of COVID-19: a retrospective study. Motoc NS, Ruta VM, Man MA, et al. Medicina (Kaunas) 2022;58:707.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9230767</ArticleId><ArticleId IdType="pubmed">35743970</ArticleId></ArticleIdList></Reference><Reference><Citation>Case study: prolonged infectious SARS-CoV-2 shedding from an asymptomatic immunocompromised individual with cancer. Avanzato VA, Matson MJ, Seifert SN, et al. Cell. 2020;183:1901–1912.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7640888</ArticleId><ArticleId IdType="pubmed">33248470</ArticleId></ArticleIdList></Reference><Reference><Citation>SARS-CoV-2 evolution and immune escape in immunocompromised patients. Scherer EM, Babiker A, Adelman MW, et al. N Engl J Med. 2022;386:2436–2438.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9202319</ArticleId><ArticleId IdType="pubmed">35675197</ArticleId></ArticleIdList></Reference><Reference><Citation>SARS-CoV-2 prolonged infection during advanced HIV disease evolves extensive immune escape. Cele S, Karim F, Lustig G, et al. Cell Host Microbe. 2022;30:154–162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8758318</ArticleId><ArticleId IdType="pubmed">35120605</ArticleId></ArticleIdList></Reference><Reference><Citation>Persistent SARS-CoV-2 infection in immunocompromised patients facilitates rapid viral evolution: Retrospective cohort study and literature review. Hettle D, Hutchings S, Muir P, Moran E. Clin Infect Pract. 2022;16:100210.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9666269</ArticleId><ArticleId IdType="pubmed">36405361</ArticleId></ArticleIdList></Reference><Reference><Citation>SARS-CoV-2 variants in patients with immunosuppression. Corey L, Beyrer C, Cohen MS, Michael NL, Bedford T, Rolland M. N Engl J Med. 2021;385:562–566.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8494465</ArticleId><ArticleId IdType="pubmed">34347959</ArticleId></ArticleIdList></Reference><Reference><Citation>Generation of SARS-CoV-2 escape mutations by monoclonal antibody therapy. Ragonnet-Cronin M, Nutalai R, Huo J, et al. Nat Commun. 2023;14:3334.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10246534</ArticleId><ArticleId IdType="pubmed">37286554</ArticleId></ArticleIdList></Reference><Reference><Citation>Host immunological responses facilitate development of SARS-CoV-2 mutations in patients receiving monoclonal antibody treatments. Gupta A, Konnova A, Smet M, et al. J Clin Invest. 2023;133:166032.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10014108</ArticleId><ArticleId IdType="pubmed">36727404</ArticleId></ArticleIdList></Reference><Reference><Citation>Long-term evolution of SARS-CoV-2 in an immunocompromised patient with non-Hodgkin lymphoma. Borges V, Isidro J, Cunha M, et al. mSphere. 2021;6:24421.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8386466</ArticleId><ArticleId IdType="pubmed">34319130</ArticleId></ArticleIdList></Reference><Reference><Citation>Structural landscape of NSP coding genomic regions of SARS-CoV-2-ssRNA genome: a structural genomics approach toward identification of druggable genome, ligand-binding pockets, and structure-based druggability. Chakraborty C, Bhattacharya M, Sharma AR, Chatterjee S, Agoramoorthy G, Lee SS. Mol Biotechnol. 2024;66:641–662.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9735222</ArticleId><ArticleId IdType="pubmed">36463562</ArticleId></ArticleIdList></Reference><Reference><Citation>Structural biology of SARS-CoV-2: open the door for novel therapies. Yan W, Zheng Y, Zeng X, He B, Cheng W. Signal Transduct Target Ther. 2022;7:26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8793099</ArticleId><ArticleId IdType="pubmed">35087058</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>